Search

Your search keyword '"Zurita, Amado"' showing total 363 results
Start Over Author "Zurita, Amado"
363 results on '"Zurita, Amado"'

1. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

Author

Alhalabi, Omar, Groisberg, Roman, Zinner, Ralph, Hahn, Andrew W., Naing, Aung, Zhang, Shizhen, Tsimberidou, Apostolia M., Rodon, Jordi, Fu, Siqing, Yap, Timothy A., Hong, David S., Sun, Ming, Jiang, Yunfang, Pant, Shubham, Shah, Amishi Y., Zurita, Amado, Tannir, Nizar M., Vikram, Raghunandan, Roszik, Jason, Meric-Bernstam, Funda, and Subbiah, Vivek

Published
2023
Full Text
View/download PDF

2. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Author

Karam, Jose A., Msaouel, Pavlos, Haymaker, Cara L., Matin, Surena F., Campbell, Matthew T., Zurita, Amado J., Shah, Amishi Y., Wistuba, Ignacio I., Marmonti, Enrica, Duose, Dzifa Y., Parra, Edwin R., Soto, Luisa Maren Solis, Laberiano-Fernandez, Caddie, Lozano, Marisa, Abraham, Alice, Hallin, Max, Chin, Curtis D., Olson, Peter, Der-Torossian, Hirak, Yan, Xiaohong, Tannir, Nizar M., and Wood, Christopher G.

Published
2023
Full Text
View/download PDF

3. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy

Author

Hahn, Andrew W., Kotecha, Ritesh R., Viscuse, Paul V., Pieretti, Alberto C., Wiele, Andrew J., Jonasch, Eric, Lee, Chung-Han, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Campbell, Matthew T., Sharma, Padmanee, Motzer, Robert J., Russo, Paul, Wood, Christopher G., Tannir, Nizar M., Voss, Martin H., Karam, Jose A., Hakimi, A. Ari, and Msaouel, Pavlos

Published
2023
Full Text
View/download PDF

4. Archival single-cell genomics reveals persistent subclones during DCIS progression

Author

Wang, Kaile, Kumar, Tapsi, Wang, Junke, Minussi, Darlan Conterno, Sei, Emi, Li, Jianzhuo, Tran, Tuan M., Thennavan, Aatish, Hu, Min, Casasent, Anna K., Xiao, Zhenna, Bai, Shanshan, Yang, Lei, King, Lorraine M., Shah, Vandna, Kristel, Petra, van der Borden, Carolien L., Marks, Jeffrey R., Zhao, Yuehui, Zurita, Amado J., Aparicio, Ana, Chapin, Brian, Ye, Jie, Zhang, Jianjun, Gibbons, Don L., Sawyer, Ellinor, Thompson, Alastair M., Futreal, Andrew, Hwang, E. Shelley, Wesseling, Jelle, Lips, Esther H., and Navin, Nicholas E.

Published
2023
Full Text
View/download PDF

7. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

Author

Dayyani, Farshid, Zurita, Amado J, Nogueras-González, Graciela M, Slack, Rebecca, Millikan, Randall E, Araujo, John C, Gallick, Gary E, Logothetis, Christopher J, and Corn, Paul G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Biomarkers, Tumor, Follow-Up Studies, Hepatocyte Growth Factor, Humans, Insulin, Male, Middle Aged, Neoplasm Grading, Osteopontin, Prognosis, Prostatic Neoplasms, Castration-Resistant, Retrospective Studies, Survival Rate, Hepatocyte growth factor, Castration resistance, Metastatic prostate cancer, Prognostic marker, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundWe hypothesized that pretreatment serum levels of insulin and other serum markers would predict Progression-free survival (PFS), defined as time to castration-resistant progression or death, in metastatic androgen-dependent prostate cancer (mADPC).MethodsSerum samples from treatment-naïve men participating in a randomized phase 3 trial of ADT +/- chemotherapy were retrospectively analyzed using multiplex assays for insulin and multiple other soluble factors. Cox proportional hazards regression models were used to identify associations between individual factor levels and PFS.ResultsSixty six patients were evaluable (median age = 72 years; median prostate surface antigen [PSA] = 31.5 ng/mL; Caucasian = 86 %; Gleason score ≥8 = 77 %). In the univariable analysis, higher insulin (HR = 0.81 [0.67, 0.98] p = 0.03) and C-peptide (HR = 0.62 [0.39, 1.00]; p = 0.05) levels were associated with a longer PFS, while higher Hepatocyte Growth Factor (HGF; HR = 1.63 [1.06, 2.51] p = 0.03) and Osteopontin (OPN; HR = 1.56 [1.13, 2.15]; p = 0.01) levels were associated with a shorter PFS. In multivariable analysis, insulin below 2.1 (ln scale; HR = 2.55 [1.24, 5.23]; p = 0.011) and HGF above 8.9 (ln scale; HR = 2.67 [1.08, 3.70]; p = 0.027) levels were associated with longer PFS, while adjusted by OPN, C-peptide, trial therapy and metastatic volume. Four distinct risk groups were identified by counting the number of risk factors (RF) including low insulin, high HGF, high OPN levels, and low C-peptide levels (0, 1, 2, and 3). Median PFS was 9.8, 2.0, 1.6, and 0.7 years for each, respectively (p

Published
2016

8. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

Author

Spetsieris, Nicholas, Boukovala, Myrto, Weldon, Justin A., Tsikkinis, Alexandros, Hoang, Anh, Aparicio, Ana, Tu, Shi-Ming, Araujo, John C., Zurita, Amado J., Corn, Paul G., Pagliaro, Lance, Kim, Jeri, Wang, Jennifer, Subudhi, Sumit K., Tannir, Nizar M., Logothetis, Christopher J., Troncoso, Patricia, Wang, Xuemei, Wen, Sijin, and Efstathiou, Eleni

Published
2021
Full Text
View/download PDF

12. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Author

Campbell, Matthew T., Matin, Surena F., Tam, Alda L., Sheth, Rahul A., Ahrar, Kamran, Tidwell, Rebecca S., Rao, Priya, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Jonasch, Eric, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Chen, Hong, Espejo, Alexsandra B., Allison, James P., Yadav, Shalini S., and Sharma, Padmanee

Published
2021
Full Text
View/download PDF

13. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, Jaalouk, Diana E, Bueso-Ramos, Carlos, Bover, Laura, Sun, Yan, Kuniyasu, Akihiko, Driessen, Wouter HP, Cardó-Vila, Marina, Rietz, Cecilia, Zurita, Amado J, O'Brien, Susan, Kantarjian, Hagop M, Cortes, Jorge E, Calin, George A, Koivunen, Erkki, Arap, Wadih, and Pasqualini, Renata

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Pediatric, Lymphoma, Prostate Cancer, Urologic Diseases, Clinical Research, Cancer, Pediatric Cancer, Rare Diseases, Hematology, Amino Acid Sequence, Antineoplastic Agents, Cell Line, Tumor, Cell Survival, Drug Screening Assays, Antitumor, Humans, Inhibitory Concentration 50, Leukemia, Ligands, Molecular Sequence Data, Peptides, Receptors, Interleukin-11, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeThe IL11 receptor (IL11R) is an established molecular target in primary tumors of bone, such as osteosarcoma, and in secondary bone metastases from solid tumors, such as prostate cancer. However, its potential role in management of hematopoietic malignancies has not yet been determined. Here, we evaluated the IL11R as a candidate therapeutic target in human leukemia and lymphoma.Experimental design and resultsFirst, we show that the IL11R protein is expressed in a variety of human leukemia- and lymphoma-derived cell lines and in a large panel of bone marrow samples from leukemia and lymphoma patients, whereas expression is absent from nonmalignant control bone marrow. Moreover, a targeted peptidomimetic prototype (termed BMTP-11), specifically bound to leukemia and lymphoma cell membranes, induced ligand-receptor internalization mediated by the IL11R, and resulted in a specific dose-dependent cell death induction in these cells. Finally, a pilot drug lead-optimization program yielded a new myristoylated BMTP-11 analogue with an apparent improved antileukemia cell profile.ConclusionsThese results indicate (i) that the IL11R is a suitable cell surface target for ligand-directed applications in human leukemia and lymphoma and (ii) that BMTP-11 and its derivatives have translational potential against this group of malignant diseases.

Published
2015

14. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial

Author

Corn, Paul G, Heath, Elisabeth I, Zurita, Amado, Ramesh, Naveen, Xiao, Lianchun, Sei, Emi, Li-Ning-Tapia, Elsa, Tu, Shi-Ming, Subudhi, Sumit K, Wang, Jennifer, Wang, Xuemei, Efstathiou, Eleni, Thompson, Timothy C, Troncoso, Patricia, Navin, Nicholas, Logothetis, Christopher J, and Aparicio, Ana M

Published
2019
Full Text
View/download PDF

15. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.

Author

Hahn, Andrew W, Surasi, Devaki Shilpa, Viscuse, Paul V, Bathala, Tharakeswara K, Wiele, Andrew J, Campbell, Matthew T, Zurita, Amado J, Shah, Amishi Y, Jonasch, Eric, Gao, Jianjun, Goswami, Sangeeta, Alhalabi, Omar, Rao, Priya, Sircar, Kanishka, Tannir, Nizar M, and Msaouel, Pavlos

Subjects
THERAPEUTIC use of antineoplastic agents, KIDNEY tumors, CANCER treatment, RISK assessment, SARCOMA, RESEARCH funding, CELL physiology, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, AMIDES, DESCRIPTIVE statistics, METASTASIS, IMMUNE checkpoint inhibitors, ODDS ratio, RENAL cell carcinoma, CANCER cells, CANCER patient psychology, CONFIDENCE intervals, DISEASE progression, SPECIALTY hospitals, OVERALL survival, EVALUATION
Abstract

Background Metastatic RCC with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is an aggressive disease associated with improved response to immune checkpoint therapy (ICT). The outcomes of patients treated with VEGFR-targeted therapies (TT) following ICT progression have not been investigated. Patients and Methods Retrospective review of 57 patients with sarcomatoid (S), rhabdoid (R), or sarcomatoid plus rhabdoid (S + R) dedifferentiation who received any TT after progression on ICT at an academic cancer center. Clinical endpoints of interest included time on TT, overall survival (OS) from initiation of TT, and objective response rate (ORR) by RECIST version 1.1. Multivariable models adjusted for epithelial histology, IMDC risk, prior VEGFR TT, and inclusion of cabozantinib in the post-ICT TT regimen. Results 29/57 patients had S dedifferentiation and 19 had R dedifferentiation. The most frequently used TT was cabozantinib (43.9%) followed by selective VEGFR TT (22.8%). The median time on TT was 6.4 months for all, 6.1 months for those with S dedifferentiation, 15.6 months for R dedifferentiation, and 6.1 months for S + R dedifferentiation. Median OS from initiation of TT was 24.9 months for the entire cohort, and the ORR was 20.0%. Patients with R dedifferentiation had significantly longer time on TT than those with S dedifferentiation (HR 0.44, 95% CI, 0.21-0.94). IMDC risk was associated with OS. Conclusions A subset of patients with S/R dedifferentiation derive clinical benefit from TT after they have progressive disease on ICT. Patients with R dedifferentiation appeared to derive more benefit from TT than those with S dedifferentiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics

Author

Welter, Lisa, primary, Zheng, Serena, additional, Setayesh, Sonia Maryam, additional, Morikado, Michael, additional, Agrawal, Arushi, additional, Nevarez, Rafael, additional, Naghdloo, Amin, additional, Pore, Milind, additional, Higa, Nikki, additional, Kolatkar, Anand, additional, Thiele, Jana-Aletta, additional, Sharma, Priyanka, additional, Moore, Halle C. F., additional, Richer, Jennifer K., additional, Elias, Anthony, additional, Pienta, Kenneth J., additional, Zurita, Amado J., additional, Gross, Mitchell E., additional, Shishido, Stephanie N., additional, Hicks, James, additional, Velasco, Carmen Ruiz, additional, and Kuhn, Peter, additional

Published
2023
Full Text
View/download PDF

19. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

Author

Tang, Chad, primary, Sherry, Alexander D., additional, Haymaker, Cara, additional, Bathala, Tharakeswara, additional, Liu, Suyu, additional, Fellman, Bryan, additional, Cohen, Lorenzo, additional, Aparicio, Ana, additional, Zurita, Amado J., additional, Reuben, Alexandre, additional, Marmonti, Enrica, additional, Chun, Stephen G., additional, Reddy, Jay P., additional, Ghia, Amol, additional, McGuire, Sean, additional, Efstathiou, Eleni, additional, Wang, Jennifer, additional, Wang, Jianbo, additional, Pilie, Patrick, additional, Kovitz, Craig, additional, Du, Weiliang, additional, Simiele, Samantha J., additional, Kumar, Rachit, additional, Borghero, Yerko, additional, Shi, Zheng, additional, Chapin, Brian, additional, Gomez, Daniel, additional, Wistuba, Ignacio, additional, and Corn, Paul G., additional

Published
2023
Full Text
View/download PDF

23. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical...

Author

Hoffman, Karen E., Nguyen, Paul L., Rathkopf, Dana E., Zurita, Amado J., Spratt, Daniel Eidelberg, Dess, Robert Timothy, Liauw, Stanley L., Szmulewitz, Russell Zelig, Einstein, David Johnson, Bubley, Glenn, Yu, James B., An, Yi, Wong, Anthony C., Feng, Felix Y, McKay, Rana R., Rose, Brent S., Shin, Kee-Young, Kibel, Adam S., Taplin, Mary-Ellen, and Kollmeier, Marisa

Published
2024
Full Text
View/download PDF

25. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC).

Author

Venkatesh, Neha, Tidwell, Rebecca, Yu, Yao, Aparicio, Ana, Zurita, Amado J., Subudhi, Sumit Kumar, Siddiqui, Bilal Ahmed, Gregg, Justin R., Corn, Paul Gettys, Msaouel, Pavlos, Koutroumpakis, Efstratios, McQuade, Jennifer Leigh, Frigo, Daniel, Pilié, Patrick Glen, Logothetis, Christopher, Huff, Chad, and Hahn, Andrew Warren

Published
2024
Full Text
View/download PDF

27. Abstract 125: Archival single cell sequencing reveals persistent subclones over years to decades of DCIS progression

Author

Wang, Kaile, primary, Kumar, Tapsi, additional, wang, Junke, additional, Minussi, Darlan, additional, Sei, Emi, additional, li, Jianzhuo, additional, Tran, Tuan, additional, Thennavan, Aatish, additional, Hu, Min, additional, Casasent, Anna, additional, Xiao, Zhenna, additional, Bai, Shanshan, additional, Zhao, Yuehui, additional, Zurita, Amado, additional, Aparicio, Ana, additional, Chapin, Brian, additional, ye, Jie, additional, Zhang, Jianjun, additional, Gibbons, Don, additional, Futreal, Andrew, additional, King, Lorraine, additional, Marks, Jeffrey, additional, Hwang, E. Shelley, additional, Shah, Vandna, additional, Sawyer, Ellinor, additional, Kristel, Petra, additional, Wesseling, Jelle, additional, Lips, Esther H., additional, and Navin, Nicholas, additional

Published
2023
Full Text
View/download PDF

28. Data from Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer

Author

Chai, Shoujie, primary, Matsumoto, Nicholas, primary, Storgard, Ryan, primary, Peng, Chen-Ching, primary, Aparicio, Ana, primary, Ormseth, Benjamin, primary, Rappard, Kate, primary, Cunningham, Katherine, primary, Kolatkar, Anand, primary, Nevarez, Rafael, primary, Tu, Kai-Han, primary, Hsu, Ching-Ju, primary, Malihi, Paymaneh, primary, Corn, Paul, primary, Zurita, Amado, primary, Hicks, James, primary, Kuhn, Peter, primary, and Ruiz-Velasco, Carmen, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1-5 and Table S1 from Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer

Author

Chai, Shoujie, primary, Matsumoto, Nicholas, primary, Storgard, Ryan, primary, Peng, Chen-Ching, primary, Aparicio, Ana, primary, Ormseth, Benjamin, primary, Rappard, Kate, primary, Cunningham, Katherine, primary, Kolatkar, Anand, primary, Nevarez, Rafael, primary, Tu, Kai-Han, primary, Hsu, Ching-Ju, primary, Malihi, Paymaneh, primary, Corn, Paul, primary, Zurita, Amado, primary, Hicks, James, primary, Kuhn, Peter, primary, and Ruiz-Velasco, Carmen, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

Author

Corn, Paul G., primary, Zhang, Miao, primary, Nogueras-Gonzalez, Graciela M., primary, Xiao, Lianchun, primary, Zurita, Amado J., primary, Subudhi, Sumit K., primary, Tu, Shi-Ming, primary, Aparicio, Ana M., primary, Coarfa, Cristian, primary, Rajapakshe, Kimal, primary, Huang, Shixia, primary, Navone, Nora M., primary, Lin, Sue-Hwa, primary, Wang, Guocan, primary, Ramachandran, Sumankalai, primary, Titus, Mark A., primary, Panaretakis, Theocharis, primary, Gallick, Gary E., primary, Efstathiou, Eleni, primary, Troncoso, Patricia, primary, and Logothetis, Christopher, primary

Published
2023
Full Text
View/download PDF

31. Supplemental Table 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Author

Aparicio, Ana M., primary, Harzstark, Andrea L., primary, Corn, Paul G., primary, Wen, Sijin, primary, Araujo, John C., primary, Tu, Shi-Ming, primary, Pagliaro, Lance C., primary, Kim, Jeri, primary, Millikan, Randall E., primary, Ryan, Charles, primary, Tannir, Nizar M., primary, Zurita, Amado J., primary, Mathew, Paul, primary, Arap, Wadih, primary, Troncoso, Patricia, primary, Thall, Peter F., primary, and Logothetis, Christopher J., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Data from Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer

Author

Malihi, Paymaneh D., primary, Graf, Ryon P., primary, Rodriguez, Angel, primary, Ramesh, Naveen, primary, Lee, Jerry, primary, Sutton, Ramsay, primary, Jiles, Rhett, primary, Ruiz Velasco, Carmen, primary, Sei, Emi, primary, Kolatkar, Anand, primary, Logothetis, Christopher, primary, Navin, Nicholas E., primary, Corn, Paul, primary, Aparicio, Ana M., primary, Dittamore, Ryan, primary, Hicks, James, primary, Kuhn, Peter, primary, and Zurita, Amado J., primary

Published
2023
Full Text
View/download PDF

34. Supplemental Figure 2 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figure 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Legend and Methods from Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Author

Kolonin, Mikhail G., primary, Bover, Laura, primary, Sun, Jessica, primary, Zurita, Amado J., primary, Do, Kim-Anh, primary, Lahdenranta, Johanna, primary, Cardó-Vila, Marina, primary, Giordano, Ricardo J., primary, Jaalouk, Diana E., primary, Ozawa, Michael G., primary, Moya, Catherine A., primary, Souza, Glauco R., primary, Staquicini, Fernanda I., primary, Kunyiasu, Akihiko, primary, Scudiero, Dominic A., primary, Holbeck, Susan L., primary, Sausville, Edward A., primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

37. Data from Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy

Author

Mehran, Reza, primary, Nilsson, Monique, primary, Khajavi, Mehrdad, primary, Du, Zhiqiang, primary, Cascone, Tina, primary, Wu, Hua Kang, primary, Cortes, Andrea, primary, Xu, Li, primary, Zurita, Amado, primary, Schier, Robert, primary, Riedel, Bernhard, primary, El-Zein, Randa, primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure Legends from Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy

Author

Mehran, Reza, primary, Nilsson, Monique, primary, Khajavi, Mehrdad, primary, Du, Zhiqiang, primary, Cascone, Tina, primary, Wu, Hua Kang, primary, Cortes, Andrea, primary, Xu, Li, primary, Zurita, Amado, primary, Schier, Robert, primary, Riedel, Bernhard, primary, El-Zein, Randa, primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy

Author

Mehran, Reza, primary, Nilsson, Monique, primary, Khajavi, Mehrdad, primary, Du, Zhiqiang, primary, Cascone, Tina, primary, Wu, Hua Kang, primary, Cortes, Andrea, primary, Xu, Li, primary, Zurita, Amado, primary, Schier, Robert, primary, Riedel, Bernhard, primary, El-Zein, Randa, primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

40. Data from Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Author

Kolonin, Mikhail G., primary, Bover, Laura, primary, Sun, Jessica, primary, Zurita, Amado J., primary, Do, Kim-Anh, primary, Lahdenranta, Johanna, primary, Cardó-Vila, Marina, primary, Giordano, Ricardo J., primary, Jaalouk, Diana E., primary, Ozawa, Michael G., primary, Moya, Catherine A., primary, Souza, Glauco R., primary, Staquicini, Fernanda I., primary, Kunyiasu, Akihiko, primary, Scudiero, Dominic A., primary, Holbeck, Susan L., primary, Sausville, Edward A., primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table S1 from Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Author

Kolonin, Mikhail G., primary, Bover, Laura, primary, Sun, Jessica, primary, Zurita, Amado J., primary, Do, Kim-Anh, primary, Lahdenranta, Johanna, primary, Cardó-Vila, Marina, primary, Giordano, Ricardo J., primary, Jaalouk, Diana E., primary, Ozawa, Michael G., primary, Moya, Catherine A., primary, Souza, Glauco R., primary, Staquicini, Fernanda I., primary, Kunyiasu, Akihiko, primary, Scudiero, Dominic A., primary, Holbeck, Susan L., primary, Sausville, Edward A., primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure S1 from Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Author

Kolonin, Mikhail G., primary, Bover, Laura, primary, Sun, Jessica, primary, Zurita, Amado J., primary, Do, Kim-Anh, primary, Lahdenranta, Johanna, primary, Cardó-Vila, Marina, primary, Giordano, Ricardo J., primary, Jaalouk, Diana E., primary, Ozawa, Michael G., primary, Moya, Catherine A., primary, Souza, Glauco R., primary, Staquicini, Fernanda I., primary, Kunyiasu, Akihiko, primary, Scudiero, Dominic A., primary, Holbeck, Susan L., primary, Sausville, Edward A., primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy

Author

Mehran, Reza, primary, Nilsson, Monique, primary, Khajavi, Mehrdad, primary, Du, Zhiqiang, primary, Cascone, Tina, primary, Wu, Hua Kang, primary, Cortes, Andrea, primary, Xu, Li, primary, Zurita, Amado, primary, Schier, Robert, primary, Riedel, Bernhard, primary, El-Zein, Randa, primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy

Author

Mehran, Reza, primary, Nilsson, Monique, primary, Khajavi, Mehrdad, primary, Du, Zhiqiang, primary, Cascone, Tina, primary, Wu, Hua Kang, primary, Cortes, Andrea, primary, Xu, Li, primary, Zurita, Amado, primary, Schier, Robert, primary, Riedel, Bernhard, primary, El-Zein, Randa, primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

47. Body composition as a determinant of the therapeutic index with androgen signaling inhibition

Author

Hahn, Andrew W., Tidwell, Rebecca S., Pilie, Patrick G., Yu, Yao, Liu, Jingjing, Surasi, Devaki Shilpa, Titus, Mark, Zhang, Jianhua, Venkatesh, Neha, Panaretakis, Theocharis, Gregg, Justin R., Zurita, Amado J., Siddiqui, Bilal A., Corn, Paul G., Subudhi, Sumit K., Msaouel, Pavlos, Koutroumpakis, Efstratios, Huff, Chad D., Aparicio, Ana, McQuade, Jennifer L., Frigo, Daniel E., and Logothetis, Christopher J.

Abstract

Background: Androgen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI. We hypothesized that host adiposity and androgen synthesis are linked to the efficacy and toxicity of ASI for men with metastatic castration-resistant prostate cancer (mCRPC). Methods: A post-hoc analysis was done of NCT02703623 where men with mCRPC (n= 186) were treated for 8 weeks with abiraterone acetate, prednisone, and apalutamide (AAPA), and a satisfactory response was defined as a PSA decline >50%. Body composition was measured on baseline CT scans. Germline DNA WES was performed with a focus on variants in steroidogenic genes. Adipokine levels were measured in pre-treatment plasma. Results: Germline polymorphisms in 3 genes involved in androgen synthesis (AKR1C3rs12529, CYP17A1rs6162, SRD5A2rs523349) were associated with differences in body composition at baseline on ADT alone (prior to receipt of AAPA). Elevated subcutaneous adipose tissue index (SATi, p= 0.02), visceral adipose tissue index (VATi, p= 0.03), and BMI (p= 0.04) were associated with satisfactory response to AAPA. Leptin had positive correlation with VATi (r= 0.47) and SATi (r= 0.48). Conclusion: Inherited polymorphisms in androgen synthesis correlated with differences in body composition after exposure to ADT and warrant further investigation as candidate markers for body composition toxicity. Elevated subcutaneous and visceral adiposity were associated with improved response to ASI.

Published
2024
Full Text
View/download PDF

49. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Author

Nguyen, Paul L., primary, Kollmeier, Marisa, additional, Rathkopf, Dana E., additional, Hoffman, Karen E., additional, Zurita, Amado J., additional, Spratt, Daniel Eidelberg, additional, Dess, Robert Timothy, additional, Liauw, Stanley L., additional, Szmulewitz, Russell Zelig, additional, Einstein, David Johnson, additional, Bubley, Glenn, additional, Yu, James B., additional, An, Yi, additional, Wong, Anthony C., additional, Feng, Felix Y, additional, McKay, Rana R., additional, Rose, Brent S., additional, Shin, Kee-Young, additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2023
Full Text
View/download PDF

50. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

Author

Wang, Jianbo, primary, Campbell, Matthew T, additional, Shah, Amishi Yogesh, additional, Goswami, Sangeeta, additional, Msaouel, Pavlos, additional, Alhalabi, Omar, additional, Hahn, Andrew Warren, additional, Kovitz, Craig A., additional, Jana, Bagi RP, additional, Araujo, John C., additional, Gao, Jianjun, additional, Zurita, Amado J., additional, Jonasch, Eric, additional, Corn, Paul Gettys, additional, and Tannir, Nizar M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results